• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Balkan journal of medical genetics: BJMG >THE FREQUENCY OF EGFR AND KRAS MUTATIONS IN THE TURKISH POPULATION WITH NON-SMALL CELL LUNG CANCER AND THEIR RESPONSE TO ERLOTINIB THERAPY
【24h】

THE FREQUENCY OF EGFR AND KRAS MUTATIONS IN THE TURKISH POPULATION WITH NON-SMALL CELL LUNG CANCER AND THEIR RESPONSE TO ERLOTINIB THERAPY

机译：用非小细胞肺癌的土耳其人群EGFR和KRAS突变的频率及其对厄洛替尼治疗的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, profiles of epidermal growth factor receptor (EGFR) and Kirsten ras sarcoma (KRAS) mutations and response to erlotinib therapy have been investigated in patients with non-small cell lung cancer (NSCLC). DNA from 300 patients with NSCLC was extracted from paraf-fin-embedded tissues. After the extracted DNA was sequenced by pyrosequencing method, a total of 97 (32.0%) patients out of 300 were detected to carry an EGFR mutation and 75 (25.0%) patients out of 300 carried a KRAS mutation; 20 (6.6%) patients were detected to carry both of EGFR and KRAS mutations. The EGFR mutations were found to be statistically significant in female patients (48.0 women vs. 28.0% men, non smokers (49.0 vs. 26.0%) and adenocarcinoma (37.8 vs. squamous 26.8%). The overall rate of survival in patients receiving erlotinib therapy than in patients who did not. In patients without the KRAS mutation, the median overall survival rate was 161 +/- 30 weeks with erlotinib therapy and 90 +/- 13 weeks in patients without erlotinib therapy. In patients having KRAS mutation, the median overall survival was 98 +/- 16 weeks with erlotinib therapy and 34 +/- 16 weeks with no erlotinib therapy. In our study, we once again demonstrated that the presence of these mutations affected response to erlotinib therapy. The KRAS mutations negatively affected survival rate with and without erlotinib therapy.
机译：在本研究中，已经研究了非小细胞肺癌（NSCLC）的表皮生长因子受体（EGFR）和Kirsten Ras Sarcoma（KRAS）突变和对厄洛替尼治疗的反应的谱。来自300例NSCLC患者的DNA从PARAFF翅片组织中提取。通过焦磷酸法测序提取的DNA后，总共97例（32.0％）患者的300例，携带EGFR突变，75例（25.0％）患者中的300例患有KRAS突变;检测到20（6.6％）患者以携带EGFR和KRAS突变。发现EGFR突变在女性患者中存在统计学意义（48.0个妇女与28.0％的男性，非吸烟者（49.0与26.0％）和腺癌（37.8与鳞状26.8％）。接受奥尔洛替尼的患者的总体存活率疗法比没有的患者。在没有克拉斯突变的患者中，中位数生存率为161 +/- 30周，欧洲毒素疗法和90 +/- 13周，没有orlotinib疗法。在患者患有KRAS突变的患者中，中位数总生存率为98 +/- 16周，欧洲毒素治疗和34 +/- 16周，没有奥尔洛替尼治疗。在我们的研究中，我们再次表明，这些突变的存在影响了对厄洛替尼治疗的反应。克拉斯突变受到负面影响生存率和没有orlotinib疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号